Business
Breast Cancer Collaboration
Breast Cancer Collaboration.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 1072S Angle PLC 19 September 2014 \n\n \n\n\n\n\nFor immediate release\n\n\n 19 September 2014\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nBREAST CANCER COLLABORATION WITH THE UNIVERSITY OF SOUTHERN CALIFORNIA NORRIS COMPREHENSIVE CANCER CENTER \n \nANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce it has signed a collaboration agreement with the University of Southern California (USC) Norris Comprehensive Cancer Center to investigate the clinical use of the Parsortix system for breast cancer. \n \nThe USC Norris Comprehensive Cancer Center (USC Norris) is a world leader in cancer research and is designated by the National Cancer Institute as one of the nation's leading comprehensive cancer centers.\n \nThe research collaboration will be led by Dr Julie E. Lang, M.D., F.A.C.S., Associate Professor of Surgery, specialising in breast cancer and notably in molecular profiling of circulating tumor cells in breast cancer, inflammatory breast cancer and radiation induced-sarcoma. Dr Lang is involved with clinical trials and translational studies focused on finding better treatments for breast cancer patients via a multidisciplinary and personalised approach.\n \nMetastasis is responsible for virtually all breast cancer related deaths. American Society for Clinical Oncology guidelines now call for the biopsy of metastatic sites (the secondary cancer locations) for biomarker testing to guide decision making for systemic therapy. These metastatic biopsies are invasive, often requiring surgery, and therefore can cause the patient considerable additional complications. Furthermore, such metastatic biopsies can be expensive and may delay aspects of the patient's ongoing treatment. \n \nThe metastatic biopsy yields no medical benefit other than a better understanding of the status of the disease to aid therapeutic decisions, such as the most appropriate chemotherapy regime. Dr Lang and her team have investigated over several years the possibility of securing the same or similar information from circulating tumour cells (CTCs) obtained from the patient's blood through a simple blood test. In pursuing this area of research, USC Norris has used the existing in-market CTC system along with several other system...